SCHEMBL964364

SCHEMBL964364

CSc1nc(N)nc(NC(=O)[C@H](CCCN)Nc2cccc(C(F)(F)F)c2)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.45
▸ HPGD P15428 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ PKM P14618 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ THRB P10828 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ ALDH1A1 P00352 6/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MAPT P10636 6/20 0.37
▸ RXFP1 Q9HBX9 3/20 0.37
▸ TP53 P04637 2/20 0.37
▸ HSD17B10 Q99714 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964828 0.98 HPGD (0.44) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL3459382 0.98 HPGD (0.44) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL964362 0.94 SMN1; SMN2 (0.47) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL3459376 0.91 SMN1; SMN2 (0.46) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL964825 0.91 SMN1; SMN2 (0.46) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL10180841 0.91 KMT2A (0.43) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL966008 0.90 KMT2A (0.42) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL10181411 0.89 CTSK (0.42) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL3459112 0.88 HPGD (0.46) KMT2AHPGDSMN1; SMN2MEN1PKM
SCHEMBL10180039 0.88 CA1 (0.44) KMT2AHPGDSMN1; SMN2MEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678168-B1 P70S6 KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2012-07-11 — — EP claimed
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EXELIXIS, INC. (US) 2011-01-27 — — US claimed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US claimed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EEF2K, RPS6KA3, MTOR KMT2A 3420/4885HPGD 2836/4885SMN1; SMN2 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback